<code id='99EF3E6D75'></code><style id='99EF3E6D75'></style>
    • <acronym id='99EF3E6D75'></acronym>
      <center id='99EF3E6D75'><center id='99EF3E6D75'><tfoot id='99EF3E6D75'></tfoot></center><abbr id='99EF3E6D75'><dir id='99EF3E6D75'><tfoot id='99EF3E6D75'></tfoot><noframes id='99EF3E6D75'>

    • <optgroup id='99EF3E6D75'><strike id='99EF3E6D75'><sup id='99EF3E6D75'></sup></strike><code id='99EF3E6D75'></code></optgroup>
        1. <b id='99EF3E6D75'><label id='99EF3E6D75'><select id='99EF3E6D75'><dt id='99EF3E6D75'><span id='99EF3E6D75'></span></dt></select></label></b><u id='99EF3E6D75'></u>
          <i id='99EF3E6D75'><strike id='99EF3E6D75'><tt id='99EF3E6D75'><pre id='99EF3E6D75'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:focus    Page View:3
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In